Phase 1Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors
- Sponsor
- MOMA Therapeutics (Industry)
- Enrollment
- 132 planned
- Conditions
- Advanced Solid Tumor; Metastatic Solid Tumor; Endometrial Cancer; MSI-H Cancer; Colorectal Cancer; Gastric Cancer; dMMR Cancer
- Interventions
- MOMA-341; Irinotecan; Immunotherapy
- Ages
- adults, older adults
- Registry
- NCT06974110
Full record on ClinicalTrials.gov
From the registry
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients with microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.
Primary outcomes
- Number of participants with AEs, dose-limiting toxicities (DLTs), serious AEs (SAEs), and/or AEs leading to discontinuation
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered
In the news
ResearchCell Metabolism (opens Cell Metabolism in a new tab)
Researchers report that 16-hour fasting improves cancer immunotherapy
The research included both mice and humans.
